FDA Approves First New Pain Medication in 25 Years
A Breakthrough in Pain Relief
The U.S. Food and Drug Administration (FDA) has approved suzetrigine, the first new type of pain reliever in over two decades. This non-opioid medication, developed by Vertex Pharmaceuticals, provides an alternative for managing acute pain without the risk of addiction.
Marketed under the brand name Journavx, suzetrigine is a 50-milligram prescription pill taken every 12 hours after an initial larger dose.
Why This Approval Matters
Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, emphasized the importance of this approval:
“A new non-opioid analgesic for acute pain offers an opportunity to mitigate certain risks associated with using opioids and provides patients with another treatment option.”
This move aligns with the FDA’s efforts to combat the opioid crisis by promoting safer pain management alternatives.
How Suzetrigine Works
Unlike opioids, which dull pain by acting on the brain, suzetrigine targets pain at its source by blocking pain-signaling nerves before they can transmit pain messages to the brain.
Dr. Sergio Bergese, an anesthesiologist at Stony Brook University, explained:
“This drug interrupts the pain pathway so that even though the tissue injury exists, the brain doesn’t recognize it as pain.”
Crucially, suzetrigine does not produce euphoria or a “high,” reducing the risk of dependence and addiction.
Inspired by a Rare Genetic Mutation
The breakthrough behind suzetrigine stemmed from a Pakistani family with a rare genetic condition. Members of this family could walk on hot coals without experiencing pain due to a mutation in their sodium channels—the same channels responsible for transmitting pain signals.
■ Related News
This discovery led researchers to develop suzetrigine, which works by blocking a specific sodium channel that only carries pain signals, leaving other sensations like heat and touch unaffected.
Dr. Stephen Waxman of Yale University described it as a major advancement:
“This provides proof of concept that a sodium-channel blocker can reduce pain in humans, opening the door for even more effective medications in the future.”
How Effective Is Suzetrigine?
Suzetrigine has been tested in multiple clinical trials, including:
- Post-Surgical Pain Relief
- In two studies with 600 participants, suzetrigine reduced pain as effectively as Vicodin (a combination of acetaminophen and the opioid hydrocodone).
- Participants reported about a 50% reduction in pain levels.
- Chronic Pain & Sciatica
- A smaller study on sciatica patients showed mixed results, with pain reduction similar to a placebo.
- Vertex Pharmaceuticals insists ongoing research suggests the drug may work for other types of chronic pain, including diabetic neuropathy.
Dr. Kimberley Mauer, an anesthesiologist at Oregon Health & Science University, highlighted the significance:
“The more options we have, the better we’re able to treat each and every patient.”
Availability & Cost
- Pricing: $15.50 per 50-mg pill
- Insurance Coverage: Still uncertain; patient assistance programs will be available
Dr. Mauer cautioned that insurance coverage could impact access:
“It might limit some patients from getting it. We’ll have to wait and see how it plays out in the market.”
The Future of Pain Management
Suzetrigine represents a significant step toward safer pain relief options, particularly as the medical community seeks alternatives to opioids.
With this approval, researchers hope to develop even better non-opioid painkillers, offering relief without the risks of addiction.
